Sal 003
(Synonyms: (2E)-3-苯基-N-[2,2,2-三氯-1-[[[(4-氯苯基)氨基]硫代甲酰基]氨基]乙基]-2-丙烯酰胺) 目录号 : GC14321
An inhibitor of eIF2α dephosphorylation
Cas No.:1164470-53-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Eukaryotic initiation factor 2 α-subunit (eIF2α) plays a critical role in the regulation of protein synthesis. Moreover, it also plays an important role in synaptic plasticity and long-term memory consolidation. Sal003 is a selective inhibitor of eIF2α dephosphorylation.
In vitro: Sal003 specifically prevents dephosphorylation of eIF2α by blocking eIF2α phosphatases. In Sal003-treated cells polysomes dissociated and consistent with this β-actin mRNA shifted to lighter fractions, reflecting the inhibition of general translation [1].
In vivo: Intra-basolateral amygdala (BLA) infusions of Sal003 immediately after memory retrieval disrupted the reconsolidation of morphine- or cocaine-induced CPP, leading to a long-lasting suppression of drug-paired stimulus-induced craving. Moreover, inhibition of eIF2α dephosphorylation in the BLA immediately after light/tone stimulus retrieval decreased subsequent cue-induced heroin-seeking behavior in the self-administration procedure. These results demonstrate that eIF2α dephosphorylation in the BLA mediates the memory reconsolidation of drug-paired stimuli [1].
Clinical trials: Currenlty no clinical data are available.
Reference:
[1] Jian M, Luo YX, Xue YX, Han Y, Shi HS, Liu JF, Yan W, Wu P, Meng SQ, Deng JH, Shen HW, Shi J, Lu L. eIF2α dephosphorylation in basolateral amygdala mediates reconsolidation of drug memory. J Neurosci. 2014;34(30):10010-21.
| Cas No. | 1164470-53-4 | SDF | |
| 别名 | (2E)-3-苯基-N-[2,2,2-三氯-1-[[[(4-氯苯基)氨基]硫代甲酰基]氨基]乙基]-2-丙烯酰胺 | ||
| 化学名 | (E)-3-phenyl-N-[2,2,2-trichloro-1-[(4-chlorophenyl)carbamothioylamino]ethyl]prop-2-enamide | ||
| Canonical SMILES | C1=CC=C(C=C1)C=CC(=O)NC(C(Cl)(Cl)Cl)NC(=S)NC2=CC=C(C=C2)Cl | ||
| 分子式 | C18H15Cl4N3OS | 分子量 | 463.21 |
| 溶解度 | ≥ 20.15mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1588 mL | 10.7942 mL | 21.5885 mL |
| 5 mM | 0.4318 mL | 2.1588 mL | 4.3177 mL |
| 10 mM | 0.2159 mL | 1.0794 mL | 2.1588 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。